Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INDIGO phase 3 trial of XmAb5871 in IgG4-related disease
2017-002214-31Phase 3Terminated
- Sponsor
- Xencor
- Start
- Aug 2018
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in IgG4-related disease (IgG4-RD) comparing XmAb5871 with Placebo (2 arms). Primary endpoint: Time to IgG4-RD disease flare. Started Aug 2018; status: terminated.
02
Drugs
obexelimab
03
Conditions
IgG4-related disease (IgG4-RD)
Beyond the preview
Go deeper on 2017-002214-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002214-31.